News from elusys therapeutics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jun 01, 2015, 11:21 ET
corporate logo.

U.S. Food And Drug Administration Accepts Biologics License Application For Anthim (Obiltoxaximab)

 Elusys Therapeutics, Inc. (Elusys) today announced the U.S. Food and Drug Administration (FDA) has accepted for filing and review its...

Feb 12, 2015, 09:15 ET
corporate logo

Elusys Reports Efficacy of Its Anthrax Anti-Toxin in Post-Exposure Prophylaxis in Animal Studies

 Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, presented...

Sep 22, 2014, 11:58 ET
corporate logo. (PRNewsFoto/Elusys Therapeutics, Inc.)

Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program

 Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced it...

Apr 08, 2014, 09:00 ET
corporate logo. (PRNewsFoto/Elusys Therapeutics, Inc.)

Elusys Completes Commercial Manufacturing Process Validation for Anthrax Antitoxin ETI-204

 Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced...

Mar 10, 2014, 10:00 ET
corporate logo. (PRNewsFoto/Elusys Therapeutics, Inc.)

Elusys Receives Notice of Allowance from U.S. Patent Office for Methods of Preventing or Treating Anthrax with ETI-204, an Anti-Anthrax Antibody, via Intramuscular Injection

Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, announced that the...

Feb 05, 2014, 09:59 ET
corporate logo. (PRNewsFoto/Elusys Therapeutics, Inc.)

Elusys Completes Enrollment in Three Phase 3 Safety Studies of Its Anthrax Anti-Toxin, ETI-204, in Adult Volunteers

 Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today...

Sep 05, 2013, 13:30 ET
corporate logo. (PRNewsFoto/Elusys Therapeutics, Inc.)

Elusys Therapeutics Presents Efficacy Results And Other Key Findings On ETI-204 Anthrax Anti-Toxin

 Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, presented key...

Jul 31, 2013, 10:17 ET
corporate logo. (PRNewsFoto/Elusys Therapeutics, Inc.)

Elusys Releases New Data On Anthrax Anti-Toxin Administered Via Intramuscular Injection From Three Recent Animal Studies

 Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today released...

Sep 13, 2012, 13:54 ET
corporate logo. (PRNewsFoto/Elusys Therapeutics, Inc.)

Elusys Awarded Additional $14.5 Million Under Existing U.S. Government Contracts Supporting Expanded Human Safety Studies of ETI-204 for Treatment of Inhalational Anthrax

Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing countermeasures for biodefense, announced today that it has been...

Aug 02, 2012, 08:30 ET
corporate logo. (PRNewsFoto/Elusys Therapeutics, Inc.)

Elusys Awarded Additional $50.2 Million Under An Existing U.S. Government Contract To Support Final Stages Of Development Of ETI-204, For Treatment Of Inhalational Anthrax

Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing countermeasures for biodefense, announced today that it has been...

Oct 24, 2011, 14:41 ET
corporate logo. (PRNewsFoto/Elusys Therapeutics, Inc.)

Elusys Initiates Third Clinical Safety Study of Anthim, a New Anthrax Treatment; Company Successfully Completes Manufacturing at Commercial Scale

Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company focused on the development of antibody therapeutics, announced today that it is...

Sep 08, 2011, 10:00 ET
A F ELUSYS THERAPEUTICS, INC. LOGO ELUSYS THERAPEUTICS, INC. LOGO

corporate logo. (PRNewsFoto/Elusys Therapeutics, Inc.)[CH]
 PINE BROOK, NJ UNITED STATES
 04/20/2009

Elusys Awarded $68 Million Contract to Develop Anthim for Intramuscular Pre- and Post-Exposure Prophylaxis of Anthrax Infection

Elusys Therapeutics, Inc. (Elusys), a  biopharmaceutical company developing biodefense countermeasures, announced today that it has been...

Aug 04, 2010, 10:00 ET

Elusys Awarded Additional $40.6 Million Under Existing U.S. Government Contract to Fund Advanced Development of Anthim, a New Treatment for Anthrax

Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company, announced today that it has been awarded a second contract year of...

Jul 15, 2010, 09:07 ET
corporate logo. (PRNewsFoto/Elusys Therapeutics, Inc.)

Elusys Therapeutics and Lonza Extend Manufacturing Agreement for Anthim, a New Anthrax Treatment in Late-Stage Development

Elusys Therapeutics and Lonza today announced an agreement for the scale-up and commercial production of Anthim, a therapeutic monoclonal antibody...

Jan 04, 2010, 10:00 ET
A F ELUSYS THERAPEUTICS, INC. LOGO ELUSYS THERAPEUTICS, INC. LOGO

corporate logo. (PRNewsFoto/Elusys Therapeutics, Inc.)[CH]
 PINE BROOK, NJ UNITED STATES
 04/20/2009

Elusys Receives Contract for up to $143 Million from the U.S. Federal Government to Fund Advanced Development of Anthim(R), a New Treatment for Anthrax

Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company, announced today that it has signed a contract potentially...

Dec 07, 2009, 09:00 ET
A F ELUSYS THERAPEUTICS, INC. LOGO ELUSYS THERAPEUTICS, INC. LOGO

corporate logo. (PRNewsFoto/Elusys Therapeutics, Inc.)[CH]
 PINE BROOK, NJ UNITED STATES
 04/20/2009

Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day

Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company developing antibody-based therapies for the treatment of...

Jun 16, 2009, 08:00 ET
A F ELUSYS THERAPEUTICS, INC. LOGO ELUSYS THERAPEUTICS, INC. LOGO

corporate logo. (PRNewsFoto/Elusys Therapeutics, Inc.)[CH]
 PINE BROOK, NJ UNITED STATES
 04/20/2009

Elusys Therapeutics and Lonza Enter Into Manufacturing Agreement

PINE BROOK, N.J. and BASEL, Switzerland, June 16 /PRNewswire/ -- Elusys Therapeutics and Lonza Sales AG entered into an agreement for the...

Apr 20, 2009, 13:40 ET
A F ELUSYS THERAPEUTICS, INC. LOGO ELUSYS THERAPEUTICS, INC. LOGO

corporate logo. (PRNewsFoto/Elusys Therapeutics, Inc.)[CH]
 PINE BROOK, NJ UNITED STATES
 04/20/2009

Elusys' Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study

- Anthim Dramatically Improves Survival in Animals with Clinical Symptoms of Anthrax disease - Elusys Therapeutics, Inc. (Elusys), a...

Apr 22, 2008, 01:00 ET

Elusys' Anthim(TM) Dramatically Improves Survival of Animals Treated After Active Anthrax Infection

PINE BROOK, N.J., April 22 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company developing...

Mar 10, 2008, 01:00 ET

Elusys Therapeutics Appoints Robert Gundel as Vice President of Research

PINE BROOK, N.J., March 10 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately held biopharmaceutical company developing...